Table 2.
Clinical and pathological characteristics of the 66 patients, not receiving radiotherapy, with or without the development of local recurrence
| All | LR+RT- | LR-RT- | |
| n = 22 | n = 44 | ||
| Time to local recurrence, months | |||
| Median | 35 | - | |
| Range | 11–96 | - | |
| Follow-up, months | |||
| Median | - | 84 | |
| Range | - | 21–166 | |
| Tamoxifen | 2 | 4 | |
| Chemotherapy | 1 | 1 | |
| Tamoxifen and chemotherapy | 1 | 0 | |
| No adjuvant treatment | 18 | 39 | |
| Inclusion 1 and 2 | Inclusion 1 | Inclusion 1 | Inclusion 2 |
| Menopause | |||
| Pre | 9 | 3 | 4 |
| Post | 13 | 30 | 2 |
| Not available | 0 | 0 | 5 |
| Age at operation, years | |||
| Median | 53 | 61 | 49 |
| Range | 44–73 | 45–70 | 40–62 |
| Size, millimeters | |||
| Median | 15 | 13 | 16 |
| Range | 7–30 | 6–40 | 10–26 |
| Not available | 0 | 0 | 0 |
| Grade | |||
| 1 | 4 | 13 | 5 |
| 2 | 10 | 9 | 3 |
| 3 | 5 | 8 | 3 |
| Not available | 3 | 3 | 0 |
| Estrogen receptor | |||
| Positive | 14 | 27 | 11 |
| Negative | 8 | 6 | 0 |
| Progesterone receptor | |||
| Positive | 15 | 17 | 11 |
| Negative | 7 | 14 | 0 |
| Not available | 0 | 2 | 0 |
| Health care region | |||
| South | 9 | 21 | 11 |
| West | 13 | 10 | 0 |
| South-East | 0 | 0 | 0 |
| Stockholm | 0 | 2 | 0 |
LR-RT- = no local recurrence, no radiotherapy given; LR+RT- = local recurrence developed, no radiotherapy given.